for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE.N

Latest Trade

43.56USD

Change

0.41(+0.95%)

Volume

10,645,130

Today's Range

42.94

 - 

43.76

52 Week Range

33.36

 - 

51.86

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
43.15
Open
43.17
Volume
10,645,130
3M AVG Volume
688.51
Today's High
43.76
Today's Low
42.94
52 Week High
51.86
52 Week Low
33.36
Shares Out (MIL)
5,606.69
Market Cap (MIL)
241,984.70
Forward P/E
10.49
Dividend (Yield %)
3.61

Next Event

Q3 2021 Pfizer Inc Earnings Release

Latest Developments

更多

U.S. CDC Says Delivered 503,418,475 Doses Of Covid-19 Vaccine As Of Oct 25

U.S. CDC Says Administered 413,645,478 Doses Of Covid-19 Vaccine As Of Oct 24

U.S. CDC Says Delivered 501,613,665 Doses Of Covid-19 Vaccine As Of Oct 22

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. Its medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. In the United States, it sells its vaccines products to the federal government, centers for disease control and prevention (CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery networks.

Industry

Biotechnology & Drugs

Contact Info

235 E 42ND ST

NEW YORK, NY

10017-5703

United States

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Albert Bourla

Chairman of the Board, Chief Executive Officer

John D. Young

Chief Business Officer, Group President

Frank A. D'amelio

Chief Financial Officer, Executive Vice President - Global Supply

Angela Hwang

Group President, Pfizer Biopharmaceuticals Group

Payal Sahni

Chief Human Resource Officer, Executive Vice President

Key Stats

2.59 mean rating - 22 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

53.6K

2019

51.8K

2020

41.9K

2021(E)

80.9K
EPS (USD)

2018

3.000

2019

2.950

2020

2.220

2021(E)

4.115
Price To Earnings (TTM)
19.72
Price To Sales (TTM)
4.36
Price To Book (MRQ)
3.45
Price To Cash Flow (TTM)
13.97
Total Debt To Equity (MRQ)
56.03
LT Debt To Equity (MRQ)
50.48
Return on Investment (TTM)
8.93
Return on Equity (TTM)
7.16

Latest News

Latest News

UPDATE 4-U.S. FDA advisers back Pfizer/BioNTech COVID-19 vaccine for children

An expert panel on Tuesday voted overwhelmingly to recommend the U.S. Food and Drug Administration authorize the Pfizer Inc and BioNTech SE COVID-19 vaccine for children ages 5 to 11, saying the benefits of the shot outweigh the risks.

FACTBOX-Countries vaccinating children against COVID-19

The U.S. Food and Drug Administration's committee of outside experts will weigh in on authorisation of Pfizer Inc and BioNTech SE's COVID-19 vaccine for emergency use in children aged 5-11.

UPDATE 3-FDA says benefits outweigh risks for Pfizer/BioNTech COVID-19 vaccine in children

Scientists at the U.S. Food and Drug Administration (FDA) said on Friday that the likely benefits of giving the Pfizer/BioNTech COVID-19 vaccine to 5 to 11 year olds clearly outweigh the risks of rare cases of heart inflammation.

Pfizer/BioNTech COVID-19 vaccine shows 90.7% efficacy in trial in children

The Pfizer/BioNTech COVID-19 vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of five to 11 year olds, the U.S. drugmaker said on Friday.

UPDATE 2-Pfizer, BioNTech say COVID-19 booster shot showed high efficacy in large study

A booster dose of the COVID-19 vaccine developed by Pfizer Inc and German partner BioNTech SE restored efficacy to 95.6% against the virus, including the Delta variant, data released by the companies from a large study showed on Thursday.

Pfizer, BioNTech report high efficacy of COVID-19 booster shot in study

Pfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.

Pfizer/BioNTech COVID-19 vaccine highly protective in 12-18 age group - U.S. CDC study

The Pfizer Inc/BioNTech SE COVID-19 vaccine was 93% effective in preventing hospitalizations among those aged 12 to 18, according to an analysis released by the U.S. Centers for Disease Control and Prevention (CDC) on Tuesday.

UPDATE 2-EU plans to boost reach of Pfizer COVID-19 shot

* Also OKs ready-to-use formulation for the shot, Comirnaty (Adds details on site, formulation approval, background)

EU approves two sites for making Pfizer's COVID-19 vaccine

Europe's drug regulator said https://bit.ly/3BXTBfy on Monday it has approved two more manufacturing sites for producing the COVID-19 vaccine developed by Pfizer Inc <PFE.N and BioNTech, while also approving a ready-to-use formulation of the coronavirus shot. (Reporting...

EU regulator evaluating use of Pfizer's COVID-19 vaccine in young children

The European Union's medicines regulator said on Monday it has started evaluating the use of Pfizer Inc and BioNTech's COVID-19 vaccine in children between the ages of five and 11.

U.S. FDA considering lowering recommended age for pFizer/BioNTech COVID-19 boosters

A top U.S. Food and Drug Administration official said on Friday that the agency is considering lowering the recommended age for who should receive booster shots of the Pfizer/BioNTech COVID-19 vaccine to as young as 40 years old, based on data from Israel suggesting the...

FACTBOX-Countries vaccinating children against COVID-19

Pfizer Inc and BioNTech SE have asked U.S. regulators to authorize their COVID-19 vaccine for emergency use in children aged 5-11, with an expert panel to the Food and Drug Administration scheduled to meet later this month to review data.

UPDATE 1-Pfizer/BioNTech submit data to EMA for COVID-19 vaccine in young children

Pfizer Inc and German partner BioNTech SE said on Friday that they had submitted data supporting the use of their COVID-19 vaccine in children aged between five and less than 12 years to the European Medicines Agency.

Pfizer/BioNTech submit data to EMA for COVID-19 vaccine in kids

Pfizer Inc and German partner BioNTech SE said on Friday that they had submitted data supporting an application for use of their COVID-19 vaccine in children aged 5 to 12 years to the European Medicines Agency.

UPDATE 2-U.S. FDA advisers weigh case for booster shots of Moderna COVID-19 vaccine

Israel health officials on Thursday said booster doses of the Pfizer-BioNTech COVID-19 vaccine improved severe disease protection in people aged 40 and older, in presentations made to U.S. scientists discussing a booster dose of Moderna's vaccine.

U.S. FDA advisers weigh case for COVID-19 vaccine booster shots

Booster doses of the Pfizer Inc. -BioNTech SE COVID-19 vaccine improved severe disease protection in people aged 40 and older, Israel's Health Ministry told an outside panel of the U.S. Food and Drug Administration on Thursday.

Panama approves Pfizer COVID-19 booster for high-risk people

Panama has approved a booster dose of Pfizer Inc's COVID-19 vaccine for high-risk people, including healthcare workers, bedridden patients, nursing home residents and people over 55, health officials said on Tuesday.

Italy widens COVID-19 vaccine booster campaign to frail and over 60s

Italy has decided to provide a booster shot of Pfizer and BioNTech's COVID-19 vaccine to frail people regardless of their age as well as people aged 60 and over, the health ministry said on Friday.

UPDATE 1-U.S. CDC advisers to review Moderna, J&J COVID-19 booster shots this month

Independent advisers to the U.S. Centers for Disease Control and Prevention will meet later this month to make recommendations on booster doses of Moderna Inc and Johnson & Johnson's COVID-19 vaccines, the agency said on Friday.

UPDATE 4-Pfizer, BioNTech seek U.S. COVID-19 vaccine clearance for children 5-11

Pfizer Inc and BioNTech SE have asked U.S. regulators to authorize emergency use of their COVID-19 vaccine for children ages 5 to 11, a group for whom no shot is currently allowed, Pfizer said on Thursday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up